XTNT Stock Overview
Provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Xtant Medical Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.40 |
| 52 Week High | US$1.45 |
| 52 Week Low | US$0.39 |
| Beta | 0.38 |
| 11 Month Change | -27.33% |
| 3 Month Change | -40.51% |
| 1 Year Change | -69.13% |
| 33 Year Change | -49.50% |
| 5 Year Change | -77.16% |
| Change since IPO | -99.91% |
Recent News & Updates
Shareholder Returns
| XTNT | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -8.0% | 1.5% | 2.2% |
| 1Y | -69.1% | 20.9% | 31.7% |
Return vs Industry: XTNT underperformed the US Medical Equipment industry which returned 21.4% over the past year.
Return vs Market: XTNT underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| XTNT volatility | |
|---|---|
| XTNT Average Weekly Movement | 12.7% |
| Medical Equipment Industry Average Movement | 8.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: XTNT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: XTNT's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 211 | Sean Browne | www.xtantmedical.com |
Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications.
Xtant Medical Holdings, Inc. Fundamentals Summary
| XTNT fundamental statistics | |
|---|---|
| Market cap | US$57.65m |
| Earnings (TTM) | -US$17.59m |
| Revenue (TTM) | US$113.86m |
0.5x
P/S Ratio-3.1x
P/E RatioIs XTNT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XTNT income statement (TTM) | |
|---|---|
| Revenue | US$113.86m |
| Cost of Revenue | US$44.53m |
| Gross Profit | US$69.33m |
| Other Expenses | US$86.92m |
| Earnings | -US$17.59m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.13 |
| Gross Margin | 60.89% |
| Net Profit Margin | -15.45% |
| Debt/Equity Ratio | 76.1% |
How did XTNT perform over the long term?
See historical performance and comparison